Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations

References

• Prevnar 13 (pneumococcal 13-valent conjugate vaccine [diphtheria CRM₁₉₇ protein]). Full Prescribing Information, Pfizer Inc, Collegeville, PA, 2016.
   Google Scholar
• Granstrom M, Thoren M, Blennow M, Tiru M, Sato Y. Acellular pertussis vaccine in adults: adverse reactions and immune response. Eur J Clin Microbiol. 1987;6(1):18–21. doi:10.1007/BF02097184. PMID:2883004.
   PubMedGoogle Scholar
• Pappenheimer AM, Jr. Diphtheria. In: Germanier R, editor. Bacterial Vaccines. Orlando, FL, USA: Academic Press, Inc.; 1984. p. 1–34.
   Google Scholar
• Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jayawardene D, Devlin C, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine. 2013;31(35):3577–84. doi:10.1016/j.vaccine.2013.04.085. PMID:23688526.
   PubMed Web of Science ®Google Scholar
• Bryant KA, Frenck R, Gurtman A, Rubino J, Treanor J, Thompson A, Jones TR, Sundaraiyer V, Baxter LM, Gruber WC, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18–49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine. Vaccine. 2015;33(43):5854–60. doi:10.1016/j.vaccine.2015.08.080. PMID:26362099.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Gurtman A, van Cleeff M, Frenck RW, Treanor J, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine. 2013;31(35):3594–602. doi:10.1016/j.vaccine.2013.04.084. PMID:23688525.
   PubMed Web of Science ®Google Scholar
• Juergens C, de Villiers PJT, Moodley K, Jayawardene D, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: a randomized open-label trial. Hum Vaccin Immunother. 2014;10(5):1343–53. doi:10.4161/hv.27998. PMID:24576885.
   PubMed Web of Science ®Google Scholar
• Shiramoto M, Irie S, Juergens C, Yamaji M, Tamai S, Aizawa M, Belanger T, Gruber WC, Scott DA, Schmoele-Thoma B. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged ≥50 years: an open-label trial. Hum Vaccin Immunother. 2014;10(7):1850–8. doi:10.4161/hv.28633. PMID:25424792.
   PubMed Web of Science ®Google Scholar
• Shiramoto M, Hanada R, Juergens C, Shoji Y, Yoshida M, Ballan B, Cooper D, Gruber WC, Scott DA, Schmoele-Thoma B. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults. Hum Vaccin Immunother. 2015;11(9):2198–206. doi:10.1080/21645515.2015.1030550. PMID:26176163.
   PubMed Web of Science ®Google Scholar
• Tinoco JC, Juergens C, Ruiz Palacios GM, Vazquez-Narvaez J, Enkerlin-Pauwells HL, Sundaraiyer V, Pathirana S, Kalinina E, Gruber WC, Scott DA, et al. Open-label trial of immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults ≥ 50 years of age in Mexico. Clin Vaccine Immunol. 2015;22(2):185–92. doi:10.1128/CVI.00711-14. PMID:25499011.
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Flamaing J, Rumke HC, Penzes J, Juergens C, Wenz A, Jayawardene D, Giardina P, Emini EA, Gruber WC, et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years. Vaccine. 2011;29(32):5195–202. doi:10.1016/j.vaccine.2011.05.031. PMID:21619909.
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Pauksens K, Juergens C, Jayawardene D, Scott D, Gruber W, Schmoele-Thoma B. Safety of a 13-valent pneumococcal conjugate vaccine in elderly adults previously immunized with a 23-valent pneumococcal polysaccharide vaccine: an open-label trial. World J Vaccine. 2013;3(4):123–9. doi:10.4236/wjv.2013.34017.
   Google Scholar
• Jackson LA, Gurtman A, Rice K, Pauksens K, Greenberg RN, Jones TR, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine. 2013;31(35):3585–93. doi:10.1016/j.vaccine.2013.05.010. PMID:23688527.
   PubMed Web of Science ®Google Scholar
• Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AM, Sanders EA, Verheij TJ, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114–25. doi:10.1056/NEJMoa1408544. PMID:25785969.
   PubMed Web of Science ®Google Scholar
• Netherlands Pharmacovigilance Centre Lareb. Overview of reports of Adverse Events after Prevenar13® administered to a selected population of elderly. [accessed 2018 January 19] https://databankws.lareb.nl/Downloads/Signals_2015_3_Prevenar_update.pdf.
   Google Scholar
• Nissen M, Marshall H, Richmond P, Shakib S, Jiang Q, Cooper D, Rill D, Baber J, Eiden J, Gruber W, et al. A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults. Vaccine. 2015;33(15):1846–54. doi:10.1016/j.vaccine.2015.02.024. PMID:25707693.
   PubMed Web of Science ®Google Scholar
• White WG, Barnes GM, Barker E, Gall D, Knight P, Griffith AH, Morris-Owen RM, Smith JW. Reactions to tetanus toxoid. J Hyg (Lond). 1973;71(2):283–97. doi:10.1017/S0022172400022750. PMID:4515879.
   PubMedGoogle Scholar
• Keitel WA, Muenz LR, Decker MD, Englund JA, Mink CM, Blumberg DA, Edwards KM. A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response comparisons of 5 vaccines and implications for booster immunization. J Infect Dis. 1999;180(2):397–403. doi:10.1086/314869. PMID:10395855.
   PubMed Web of Science ®Google Scholar
• Baxter D. Active and passive immunity, vaccine types, excipients and licensing. Occup Med (Lond). 2007;57(8):552–6. doi:10.1093/occmed/kqm110. PMID:18045976.
   PubMed Web of Science ®Google Scholar
• Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol. 2009;9(3):213–20. doi:10.1038/nri2494. PMID:19214194.
   PubMed Web of Science ®Google Scholar
• Piccolo V, Baroni A, Russo T, Schwartz RA. Ruocco's immunocompromised cutaneous district. Int J Dermatol. 2016;55(2):135–41. doi:10.1111/ijd.13086. PMID:26475059.
   PubMed Web of Science ®Google Scholar
• Ruocco V, Brunetti G, Puca RV, Ruocco E. The immunocompromised district: a unifying concept for lymphoedematous, herpes-infected and otherwise damaged sites. J Eur Acad Dermatol Venereol. 2009;23(12):1364–73. doi:10.1111/j.1468-3083.2009.03345.x. PMID:19548975.
   PubMed Web of Science ®Google Scholar
• Cohen PR. Injection Site Lichenoid Dermatitis Following Pneumococcal Vaccination: Report and Review of Cutaneous Conditions Occurring at Vaccination Sites. Dermatol Ther (Heidelb). 2016;6(2):287–98. doi:10.1007/s13555-016-0105-x. PMID:26988991.
   PubMed Web of Science ®Google Scholar
• Cook IF. Sex differences in injection site reactions with human vaccines. Hum Vaccin. 2009;5(7):441–9. doi:10.4161/hv.8476. PMID:19377279.
   PubMed Web of Science ®Google Scholar
• Cohen S. The role of cell-mediated immunity in the induction of inflammatory responses. Parke-Davis Award Lecture, 1977. Am J Pathol. 1977;88(3):502–28. PMID:329682.
   PubMed Web of Science ®Google Scholar
• Pichichero ME. Protein carriers of conjugate vaccines: characteristics, development, and clinical trials. Hum Vaccin Immunother. 2013;9(12):2505–23. doi:10.4161/hv.26109. PMID:23955057.
   PubMed Web of Science ®Google Scholar
• Jahnmatz M, Ljungman M, Netterlid E, Jenmalm MC, Nilsson L, Thorstensson R. Pertussis-specific memory B-cell and humoral IgG responses in adolescents after a fifth consecutive dose of acellular pertussis vaccine. Clin Vaccine Immunol. 2014;21(9):1301–8. doi:10.1128/CVI.00280-14. PMID:25008903.
   PubMed Web of Science ®Google Scholar
• Meyer CU, Zepp F, Decker M, Lee M, Chang SJ, Ward J, Yoder S, Bogaert H, Edwards KM. Cellular immunity in adolescents and adults following acellular pertussis vaccine administration. Clin Vaccine Immunol. 2007;14(3):288–92. doi:10.1128/CVI.00364-06. PMID:17267589.
   PubMed Web of Science ®Google Scholar
• Hong MS, Dan JM, Choi JY, Kang I. Age-associated changes in the frequency of naive, memory and effector CD8+ T cells. Mech Ageing Dev. 2004;125(9):615–8. doi:10.1016/j.mad.2004.07.001. PMID:15491679.
   PubMed Web of Science ®Google Scholar
• Fink AL, Klein SL. Sex and gender impact immune responses to vaccines among the elderly. Physiology (Bethesda). 2015;30(6):408–16. PMID:s.
   PubMed Web of Science ®Google Scholar
• Frenck RW, Jr., Gurtman A, Rubino J, Smith W, van Cleeff M, Jayawardene D, Giardina PC, Emini EA, Gruber WC, Scott DA, et al. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. Clin Vaccine Immunol. 2012;19(8):1296–303. doi:10.1128/CVI.00176-12. PMID:22739693.
   PubMed Web of Science ®Google Scholar
• Greenberg RN, Gurtman A, Frenck RW, Strout C, Jansen KU, Trammel J, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60–64 years of age. Vaccine. 2014;32(20):2364–74. doi:10.1016/j.vaccine.2014.02.002. PMID:24606865.
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Schmoele-Thoma B. Assessment of functional antibacterial opsonophagocytic antibodies elicited by 13-valent pneumococcal conjugate vaccine administered concomitantly with trivalent influenza vaccine in a randomized clinical trial in adults aged ≥ 65 years. Vaccine. 2013;31(2):291–4. doi:10.1016/j.vaccine.2012.10.077. PMID:23123107.
   PubMed Web of Science ®Google Scholar